Edwards Lifesciences Corporation
Case Overview
23 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 12/13/2024 |
Status: | Status: Investigating |
Company Name: | Company Name: Edwards Lifesciences Corporation |
Court: | Court: Central District of California |
Case Number: | Case Number: 8:24cv02221 |
Class Period: | Class Period: 02/06/2024 - 07/24/2024 |
Ticker: | Ticker: EW |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities during the period of February 6, 2024 to July 24, 2024, inclusive (“the Class Period”). Investors have until December 13, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On July 24, 2024, Edwards Lifesciences announced its second quarter 2024 results which came in below expectations. The Company also announced lowered projections for its core Transcatheter Aortic Valve Replacement (TAVR) platform for the full year 2024. The Company attributed the TAVR setback to the “continued growth and expansion of structural heart therapies … [which] put pressure on hospital workflows.” On this news, the price of Edwards Lifesciences’ shares declined by $27.25, or approximately 31.34%, to close at $59.70 per share on July 25, 2024.
On July 24, 2024, Edwards Lifesciences announced its second quarter 2024 results which came in below expectations. The Company also announced lowered projections for its core Transcatheter Aortic Valve Replacement (TAVR) platform for the full year 2024. The Company attributed the TAVR setback to the “continued growth and expansion of structural heart therapies … [which] put pressure on hospital workflows.” On this news, the price of Edwards Lifesciences’ shares declined by $27.25, or approximately 31.34%, to close at $59.70 per share on July 25, 2024.